Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis

Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis

Blog Article

Abstract In 2020, almost half a million individuals developed rifampicin-resistant tuberculosis (RR-TB).We estimated the global burden of RR-TB over the lifetime of affected individuals.We synthesized data on incidence, case detection, and treatment outcomes in 192 countries (99.99% of global tuberculosis).

Using a mathematical model, we projected disability-adjusted life years (DALYs) over the lifetime for individuals developing tuberculosis in 2020 stratified by country, age, sex, HIV, and rifampicin resistance.Here we show that incident RR-TB in 2020 was responsible for an estimated 6.9 (95% uncertainty interval: 5.5, echofix spring reverb 8.

5) million DALYs, 44% (31, 54) of which accrued among TB survivors.We estimated an average of 17 (14, 21) DALYs per person developing RR-TB, 34% (12, 56) greater than for rifampicin-susceptible tuberculosis.RR-TB burden per 100,000 was highest in former Soviet Union countries and southern African countries.While RR-TB causes substantial short-term morbidity and mortality, nearly half of the overall disease burden of RR-TB accrues among tuberculosis survivors.

The substantial long-term health impacts among those surviving RR-TB disease suggest the need read more for improved post-treatment care and further justify increased health expenditures to prevent RR-TB transmission.